June 5, 2026 - 19:39

A first-of-its-kind study suggests a new noninvasive technique may help doctors catch a devastating intestinal disease in premature infants long before it shows up on an x-ray. The technology, known as broadband optical spectroscopy (BOS), was tested in a small human study at a Chicago children's hospital and the results were published in the Journal of Pediatric Surgery.
The condition, necrotizing enterocolitis (NEC), is a serious intestinal emergency that primarily affects babies born too early. It can progress rapidly, damaging the gut wall and leading to infection or even death. Currently, doctors rely on x-rays to confirm the diagnosis, but by the time changes are visible on an x-ray, the disease is often already advanced.
BOS works by shining light through the abdominal wall and analyzing how different wavelengths are absorbed or scattered by the tissue beneath. This gives doctors a real-time read on the health of the intestinal tissue, potentially flagging early warning signs of inflammation or reduced blood flow before the tissue is permanently damaged.
The researchers behind the study say this approach could be a game-changer for neonatal intensive care units. If confirmed in larger trials, it might allow doctors to intervene with treatments like antibiotics or temporary feeding breaks much sooner, potentially saving more babies from surgery or long-term complications. The team is now working on refining the device and planning broader studies to confirm its accuracy.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...